Investors

Benzinga Virtual HealthCare Summit 2024

Email Alerts

Stay informed and receive company updates straight to your inbox

The press releases contained in this archive reflect information as of their original publication dates. AXIM Biotechnologies undertakes no obligation to update such information except as required by law.  Current information regarding the Company’s products and regulatory status is available on this website.

Recent News

AXIM Biotechnologies CEO Issues Letter to Shareholders

  Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED...

Latest Annual Filing

Fiscal Year Ended Dec 31, 2022